Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant

Background: Current therapeutic options for advanced pancreatic cancer have been largely disappointing with modest results at best, and though adjuvant therapy remains controversial, most remain in agreement that Gemcitabine should stand as part of any combination study. The inhibitor of apop...

Full description

Bibliographic Details
Main Authors: Jonathan R. Aspe, Carlos J. Diaz Osterman, Jessica M.S. Jutzy, Simone Deshields, Sonia Whang, Nathan R. Wall
Format: Article
Language:English
Published: Taylor & Francis Group 2014-02-01
Series:Journal of Extracellular Vesicles
Subjects:
Online Access:http://www.journalofextracellularvesicles.net/index.php/jev/article/download/23244/32501